lifestyle.getpetsavvy.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer
May 1, 2026
Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting
April 22, 2026
Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
April 21, 2026
Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences
April 13, 2026
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
March 17, 2026
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
March 12, 2026
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
February 20, 2026
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants
February 19, 2026
Eupraxia Pharmaceuticals Announces Proposed Public Offering
February 18, 2026